MedTrace Logo

Study of a New MVA Vaccine for Hepatitis C Virus

NCT01296451 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-04-26

No results posted yet for this study

Summary

The study is aimed at assessing the safety of AdCh3NSmut and the new candidate vaccine MVA-NSmut when administered sequentially, or alone, to healthy volunteers and patients with hepatitis C virus infection The study also aims at assessing the cellular immune response generated by AdCh3NSmut and MVA-NSmut administered as mentioned above.

Conditions

  • Hepatitis C Infection

Interventions

BIOLOGICAL

MVA-NSmut

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

AdCh3NSmut

genetic vaccine against Hepatitis virus infection

BIOLOGICAL

AdCh3NSmut1

genetic vaccine against Hepatitis virus infection

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • University Hospital Birmingham

    collaborator OTHER

  • ReiThera Srl

    lead INDUSTRY

Principal Investigators

  • Eleanor Barnes, Dr. · University of Oxford, UK

  • Paul Klenerman, Prof. · University of Oxford, UK

  • David Gorard, Dr · Wycombe Hospital, High Wycombe, Buckinghamshire

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296451 on ClinicalTrials.gov